Skip to main content


Less metal, more options for the future

The reSept™ ASD Occluder is the first occluder with a metal-free frame designed for the closure of atrial septal defects.

ASD hole size
S = Small, M = Medium, L = Large


  • Very small defects may be found by chance and may never cause a problem.
  • Some may close on their own during childhood.
  • Medium and large defects may require a medical procedure to be closed.

When ASDs require closure, the current standard of care is to have an atrial septal occluder implanted through a minimally invasive procedure, which does not require opening the heart. However, open heart surgery may be required in some cases, based on the size and position of the defect.


  • The occluder is introduced in the body by a catheter, through a small incision in the groin, and positioned in the heart.
  • Once in place, the occluder opens up like an umbrella on each side of the hole and locks together to seal it and prevent abnormal blood flow between the upper chambers of the heart.

Septal occluders have enabled minimally invasive treatment; however, currently available options have limitations because of their metal frames.
The long-term presence of a metal frame in the heart may lead to potential complications and may limit future interventions that require a physician to cross the septum.


The reSept™ ASD Occluder is the first device with a metal-free, bioresorbable frame. This novel device aims to overcome the limitations of current ASD treatment options and offers the potential to:

  • Help reduce the risk of complications due to long-term presence of metal in the heart.
  • Enable future interventions that may not otherwise be possible due to metal barriers.

The reSept ASD Occluder

features bioresorbable filaments connecting two polyester fabric patches

Locking Mechanism
Fabric Patch
Bioresorbable Filaments
Fabric Patch
Locking Mechanism



First In Human Study: Nine adult patients have been implanted with our reSept ASD Occluder and had their ASDs successfully closed. The first patient was implanted over ten years ago. The study was conducted in Germany. View

European Registry: Six patients, including four children, have been implanted with our ASD Occluder and had their ASDs successfully closed. The first patient was implanted in March 2020. The registry was conducted in Germany and in Switzerland. View


Investigational device exemption (IDE) trial – atHeart Medical has initiated a pivotal trial in the United States, in Europe and in Canada to demonstrate the safety and efficacy of the reSept ASD Occluder to treat patients with clinically significant, isolated ASDs.

The study will enroll up to 250 patients. The US Food and Drug Administration (FDA), the French National Agency for Medicines and Health Products Safety (ANSM) and Health Canada have authorised the ASCENT ASD trial to advance to Stage 3 enrollment, following the review of data from the first 50 US and French patients.

For more information about the study and participating hospitals, please visit (NCT04591392).

atHeart Medical

Our mission is to establish the first transcatheter ASD occluder with a metal-free frame as the new standard of care for atrial septal defects (ASDs).

Based in Switzerland and in the U.S., we have assembled an exceptional team with decades of experience at medical device start-ups and major corporations.

We have initiated our ASCENT ASD pivotal trial in the United States and internationally to demonstrate the safety and efficacy of our reSept ASD Occluder for treating patients with clinically significant, isolated ASD. Our reSept ASD Occluder has received Investigational Device Exemption approval from the U.S. FDA.

Our company was founded by the Olle Larsson Holding AG (OLH), a Swiss corporate group with a diverse portfolio of companies, including medical devices, and a long-standing commitment to improve children’s health.